Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo De Giorgio

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cancers|February 27, 2026
RETREAT Score Accurately Predicts the Long-Term Risk of HCC Recurrence After Liver Transplantation: A Single-Center Real-Life ValidationFlavia Neri, Mauro Viganò, Stefania Camagni, et al.
Transplantation|August 22, 2022
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential TreatmentsFrancesco Tovoli, Dante Pio Pallotta, Vito Sansone, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 8, 2025
Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinomaRiccardo Muglia, Massimo De Giorgio, Paolo Marra, et al.
Hepatology (Baltimore, Md.)|June 2, 2026
Outcomes of Y90-radioembolization as downstaging to liver transplantation in patients with hepatocellular carcinoma and tumoral portal vein thrombosisCarlo Sposito, Giammauro Berardi, Mauro Viganò, et al.
Cancer Medicine|February 22, 2023
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantationKyunghye Bang, Andrea Casadei-Gardini, Changhoon Yoo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 17, 2026
Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group)Andrea Casadei-Gardini, Lorenzo Canova, Federica Tosi, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 1, 2019
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantationMassimo Iavarone, Federica Invernizzi, Carolin Czauderna, et al.
The Lancet. Oncology|July 3, 2020
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trialVincenzo Mazzaferro, Davide Citterio, Sherrie Bhoori, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|August 13, 2021
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective StudyMassimo Iavarone, Federica Invernizzi, Tommy Ivanics, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancers|February 27, 2026
RETREAT Score Accurately Predicts the Long-Term Risk of HCC Recurrence After Liver Transplantation: A Single-Center Real-Life ValidationFlavia Neri, Mauro Viganò, Stefania Camagni, et al.
Transplantation|August 22, 2022
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential TreatmentsFrancesco Tovoli, Dante Pio Pallotta, Vito Sansone, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 8, 2025
Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinomaRiccardo Muglia, Massimo De Giorgio, Paolo Marra, et al.
Hepatology (Baltimore, Md.)|June 2, 2026
Outcomes of Y90-radioembolization as downstaging to liver transplantation in patients with hepatocellular carcinoma and tumoral portal vein thrombosisCarlo Sposito, Giammauro Berardi, Mauro Viganò, et al.
Cancer Medicine|February 22, 2023
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantationKyunghye Bang, Andrea Casadei-Gardini, Changhoon Yoo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 17, 2026
Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group)Andrea Casadei-Gardini, Lorenzo Canova, Federica Tosi, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 1, 2019
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantationMassimo Iavarone, Federica Invernizzi, Carolin Czauderna, et al.
The Lancet. Oncology|July 3, 2020
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trialVincenzo Mazzaferro, Davide Citterio, Sherrie Bhoori, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|August 13, 2021
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective StudyMassimo Iavarone, Federica Invernizzi, Tommy Ivanics, et al.
Pageof 2